Pharma BD Deal Intelligence
AbbVie and REGENXBIO entered a global eye care collaboration to develop and commercialize RGX-314 (now ABBV-RGX-314 / surabgene lomparvovec, "sura-vec"), a one-time AAV8 gene therapy expressing an anti-VEGF antibody fragment, for wet AMD, diabetic retinopathy and other chronic retinal diseases. Announced September 13, 2021 and closed November 9, 2021, REGENXBIO received $370M upfront and is eligible for up to $1.38B in development, regulatory and commercial milestones, with 50/50 US profit sharing and tiered ex-US royalties; AbbVie leads global development and commercialization. Post-close the program has advanced materially: the wet AMD pivotal trials ATMOSPHERE and ASCENT completed enrollment (Oct 2025, >1,200 patients, the largest gene-therapy program in nAMD to date) with topline data expected in 2026. On August 5, 2025 the parties amended the agreement — in lieu of a prior $200M milestone, AbbVie will pay REGENXBIO $100M on first patient dosed in the suprachoroidal DR Phase IIb/III trial and a further $100M on first patient dosed in a subsequent Phase III trial, while AbbVie independently funds a new wet AMD Phase III trial (ACHIEVE).